Prothena Q2 net loss $54.6M, revises FY cash guidance up to ~$600M

PROTHENA CORP PUBLIC LTD CO

2023-Q2 EPS reported -$1.92 revenue$6,188,000

Net loss $54.6M ($1.03/share) vs $41.2M loss in Q2 2022; revenue $4.0M (up from $1.3M).
Cash, equivalents $661.3M at June 30; year-end cash guidance raised to ~$600M midpoint from $512M.
Bristol Myers Squibb exercised $55M option for worldwide rights to PRX005 (anti-tau) in July 2023.
PRX012 Phase 1 topline data expected year-end 2023; IND filing for PRX123 dual vaccine expected year-end.
Billy Dunn (former FDA Office of Neuroscience Director) added to Board.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

PROTHENA CORP PUBLIC LTD CO updated its the second quarter ended June 30, 2023 guidance (lowered).

Period: the second quarter ended June 30, 2023
Guidance: lowered
Result: reported results

Exact text from the filing

Prothena Corporation plc issued a press release announcing its financial results for the second quarter ended June 30, 2023.

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

PROTHENA CORP PUBLIC LTD CO filing history →

Source: SEC EDGAR

accession 0001559053-23-000025

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.